GGrantIndex
← Leaderboards

James D Brooks

Stanford University

$12,828,912
Attributed
$17,923,043
Total exposure
13
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.9M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$24,532,556 · 15

By mechanism

U01$10,963,288 · 3
U54$7,560,792 · 3
R01$2,496,164 · 3
R21$1,570,965 · 4
K12$1,303,310 · 1
P20$638,037 · 1

Top collaborators

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Sampling

Research focus

SamplingTissuesTumorBaseProstateSuccessGene ExpressionMalignant NeoplasmsCellsBiological MarkersProteinsProgramsMalignant Neoplasm Of ProstatePathway InteractionsMolecularBiologicalTechnologyHistologicBenignImageUrologicCancer PatientTrainingArea

Grant awards (52)

Stanford O'Brien Urology Research Center$1,177,081
U54 · FY2025 · DK · contact PI
Multidisciplinary K12 Urologic Research at Stanford (KUReS) Career Development Program$434,161
K12 · FY2025 · DK
Administrative Core$322,517
U54 · FY2025 · DK · contact PI
Stanford O'Brien Urology Research Center$1,194,395
U54 · FY2024 · DK · contact PI
Multidisciplinary K12 Urologic Research at Stanford (KUReS) Career Development Program$434,440
K12 · FY2024 · DK
Administrative Core$322,517
U54 · FY2024 · DK · contact PI
Identification of serum protein biomarkers by profiling N-glycoproteomes of patient-derived xenografts of neuroendocrine prostate cancer$171,759
R21 · FY2024 · CA · contact PI
Stanford O'Brien Urology Research Center$1,200,000
U54 · FY2023 · DK · contact PI
Glycosylation and Immune Evasion in Urologic Tumors$583,786
U01 · FY2023 · CA
Multidisciplinary K12 Urologic Research at Stanford (KUReS) Career Development Program$434,709
K12 · FY2023 · DK
Administrative Core$317,748
U54 · FY2023 · DK · contact PI
Identification of serum protein biomarkers by profiling N-glycoproteomes of patient-derived xenografts of neuroendocrine prostate cancer$217,991
R21 · FY2023 · CA · contact PI
Stanford O'Brien Urology Research Center$1,200,000
U54 · FY2022 · DK · contact PI
Glycosylation and Immune Evasion in Urologic Tumors$588,870
U01 · FY2022 · CA
Administrative Core$315,707
U54 · FY2022 · DK · contact PI
BMP5 cells and signaling in BPH pathogenesis$236,550
R01 · FY2022 · DK
Stanford O'Brien Urology Research Center$1,200,000
U54 · FY2021 · DK · contact PI
Glycosylation and Immune Evasion in Urologic Tumors$582,341
U01 · FY2021 · CA
Identification of serum protein biomarkers by profiling N-glycoproteomes of patient-derived xenografts of clear cell renal cell carcinoma$405,619
R21 · FY2021 · CA · contact PI
Administrative Core$310,827
U54 · FY2021 · DK · contact PI
BMP5 cells and signaling in BPH pathogenesis$236,550
R01 · FY2021 · DK
Targeting AXL to overcome resistance to taxanes and platinum-based therapy in castrate resistant and neuroendocrine prostate cancer$184,312
R21 · FY2021 · CA · contact PI
Glycosylation and Immune Evasion in Urologic Tumors$618,139
U01 · FY2020 · CA
Stanford Molecular and Cellular Characterization Laboratory$611,403
U01 · FY2020 · CA · contact PI
BMP5 cells and signaling in BPH pathogenesis$236,550
R01 · FY2020 · DK
Targeting AXL to overcome resistance to taxanes and platinum-based therapy in castrate resistant and neuroendocrine prostate cancer$221,808
R21 · FY2020 · CA · contact PI
Stanford Molecular and Cellular Characterization Laboratory$983,470
U01 · FY2019 · CA · contact PI
Glycosylation and Immune Evasion in Urologic Tumors$621,878
U01 · FY2019 · CA
DESI-MS detection of positive margins in kidney cancer$198,738
R21 · FY2019 · CA · contact PI
Stanford Molecular and Cellular Characterization Laboratory$1,013,416
U01 · FY2018 · CA · contact PI
DESI-MS detection of positive margins in kidney cancer$170,738
R21 · FY2018 · CA · contact PI
Stanford Molecular and Cellular Characterization Laboratory$699,416
U01 · FY2017 · CA · contact PI
Stanford Molecular and Cellular Characterization Laboratory$314,000
U01 · FY2017 · CA · contact PI
RNA markers of renal damage due to obstruction$237,424
R01 · FY2017 · DK · contact PI
Stanford Molecular and Cellular Characterization Laboratory$78,500
U01 · FY2017 · CA · contact PI
Stanford Molecular and Cellular Characterization Laboratory$624,820
U01 · FY2016 · CA · contact PI
RNA markers of renal damage due to obstruction$237,396
R01 · FY2016 · DK · contact PI
GENOMICS CLOUD INTEGRATION FOR THE STANFORD MOLECULAR AND CELLULAR CHARACTERIZATION LABORATORY$63,200
U01 · FY2016 · CA · contact PI
Stanford Molecular and Cellular Characterization Laboratory$799,493
U01 · FY2015 · CA · contact PI
Molecular Signatures of LUTS-associated BPH$317,037
P20 · FY2015 · DK · contact PI
RNA markers of renal damage due to obstruction$237,492
R01 · FY2015 · DK · contact PI
New Tools for Prostate Cancer Detection and Prognostication$112,120
U01 · FY2015 · CA
New Tools for Prostate Cancer Detection and Prognostication$497,815
U01 · FY2014 · CA
Molecular Signatures of LUTS-associated BPH$321,000
P20 · FY2014 · DK · contact PI
New Tools for Prostate Cancer Detection and Prognostication$505,451
U01 · FY2013 · CA
New Tools for Prostate Cancer Detection and Prognostication$538,172
U01 · FY2012 · CA
New Tools for Prostate Cancer Detection and Prognostication$558,198
U01 · FY2011 · CA
New Tools for Prostate Cancer Detection and Prognostication$568,800
U01 · FY2010 · CA
Translating Prostate Cancer Gene Expression Subtypes$262,921
R01 · FY2008 · CA · contact PI
Translating Prostate Cancer Gene Expression Subtypes$262,921
R01 · FY2007 · CA · contact PI
Translating Prostate Cancer Gene Expression Subtypes$270,774
R01 · FY2006 · CA · contact PI
Translating Prostate Cancer Gene Expression Subtypes$277,586
R01 · FY2005 · CA